Researchanalyst
07.12.2021, Author: Nico Popp

XPhyto Therapeutics - Three hot irons in the fire — Covid19 PCR rapid test in 25 minutes - hope in the fight against depression

  • Biotech

Early-stage biotech companies rarely provide detailed insights into their universe. It is not surprising, as the market for diagnostics in the context of Covid-19, in particular, is highly competitive. The company featured here, XPhyto Therapeutics Corp. is reportedly preparing to take off in the coming weeks and months in not one but two of three business areas. Specifically, it is looking at precise and rapid PCR testing that does not require a traditional lab and promises results in 25 minutes. But it is also about testing methods for other typical diseases. Regarding medications, the provider presented here is working on procedures to improve their effect on patients and even produce them more cheaply. The following report on biotech summarizes which company XPhyto wants to catch up with in the long term and the market potential. An insight into a very dynamic market.


Time to read: 11 minutes

    XPhyto Biotech Laboratory
    XPhyto and subsidiaries research solutions. Source: XPhyto Therapeutics Corp.

    Background at a glance

    XPhyto Therapeutics Corp. is a German-Canadian biotech company focused on next-generation drug formulations, diagnostics and novel pharmaceutical agents. These include precise transdermal and orally dissolvable drug formulations, rapid and cost-effective testing for infectious diseases and oral health, and standardization of new pharmaceutical agents for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development sites in North America and Europe, with an operational focus in Germany. The focus is on regulatory approval and commercialization of medical products for European markets. For example, the company plans to launch its own rapid PCR tests in the coming weeks and months. With results within 25 minutes, the company hopes to convince customers in the near future. Corresponding studies are underway in parallel with talks with interested parties. Furthermore, XPhyto is researching innovative drug delivery forms, such as patches and self-dissolving active ingredient films for application in the mouth. The goals here are fewer side effects, easier handling for patients, and lower drug manufacturing costs. Studies on efficacy are also underway here. Wholly speculative is the area of psychedelics. The company, founded in 2017, is following in the footsteps of Christian Angermayer and Peter Thiel and aims to combat illnesses such as depression with mescaline and psilocybin.

    The business segments

    Looking at the details, three main business areas can be identified: Diagnosis, Drugs, and Dosage Forms. In the area of diagnostics, the company is currently focusing on a special form of PCR test to detect Covid-19, which can be performed on-site and offers results in as little as 25 minutes. As XPhyto has several subsidiaries in Germany, there are growth opportunities, particularly in the European market. In the drug discovery area, XPhyto is researching psychoactive substances such as mescaline and psilocybin and their use against mental illness. In the area of active ingredient carriers, everything revolves around innovative dosage forms that are intended to either provide manufacturers of drugs with cost advantages or enable better bioavailability of active ingredients.1

    Investments in Germany

    The company has an agile set-up and organizes platforms that enable business scalability within critical medical applications. XPhyto operates in Canada and Germany and is the owner of the German company Vektor Pharma TF GmbH. In the field of research and development, XPhyto cooperates with the Canadian University of Alberta. There was previously a contract with the Swabian company 3a-diagnostics for the exchange of technology related to biosensors; the company was most recently acquired by XPhyto. The technology of 3a-diagnostics GmbH is used, among other things, to implement its own PCR test with results within 25 minutes. XPhyto recently raised capital, among other things, to add the company to its portfolio.2

    laboratory biotech
    View of the company's laboratory, which began research in 2017. Source: XPhyto Therapeutics Corp. © Dr. Ludwig Höllein

    Market timing and opportunities

    XPhyto operates in three areas whose markets have entirely different maturities. While the business with psychedelic drugs, for example, is dependent on approvals and the extent to which active ingredients, such as mescaline, will be approved for the therapy of mental illnesses in the respective regions of the world remains open, there are already intact markets for innovative dosage forms and also biosensors as well as other diagnostic methods.

    Diagnostics - multi-billion market

    EUR 2.7 billion

    Market size for diagnostics in 2020 in Germany alone.

    The pandemic, in particular, has set the market for antigen and PCR tests in motion and created new use cases. According to the German Diagnostics Industry Association, the market volume for corresponding diagnostics in 2020 was EUR 2.7 billion. Of this, EUR 2.39 billion was for so-called reagents and EUR 356.7 million for equipment and service. The bulk of the reagents business, EUR 875.7 million, is in the field of infectious immunology.3

    XPhyto is also active here with its rapid PCR test. Given the continued need for testing and the certainty that ideally vaccinated individuals should also be tested regularly, the market is expected to grow even faster in 2021 and 2022.

    XPhyto points out that the company's rapid PCR test can speed up many procedures and expedite a return to normal life with a higher level of safety. The company cites rapid PCR testing in airports, which provides reliable results before passengers have left the airport, as typical use cases. Such tests could also be used outside schools and universities or for hospital admissions, providing greater safety thanks to greater accuracy compared to rapid antigen tests. XPhyto's testing technology carries the CE mark and is approved for sale within the EU.

    In addition to tests for the detection of Covid-19, XPhyto is also working with 3a-diagnostics GmbH on other biosensors that can diagnose viral and bacterial infections. These include diseases such as certain inflammations in the oral cavity (peri-implantitis, periodontitis and stomatitis) as well as scarlet fever and influenza. For the size of the market, the company points to the dental services market, for example, which is expected to reach USD 698.8 billion by 2030, according to Precedence Research.4

    pcr-test corona covid19
    The developed test kit for corona PCR rapid test. Source: XPhyto Therapeutics Corp.

    Innovative dosage forms in demand

    No precise market data are available for innovative dosage forms. However, research pointed out years ago that innovative compounds from genomics and biotechnology also require the development of innovative dosage forms. As an analysis by Technical Insights, a division of Frost & Sullivan, showed back in 2005, numerous benefits can result from innovations in dosage forms. Examples include simplified handling, fewer side effects and lower costs.

    XPhyto is addressing this point and, in addition to active ingredient patches, has also developed self-dissolving active ingredient films that release active ingredients sublingually, i.e. under the tongue. All dosage forms were developed by XPhyto's German subsidiary Vektor Pharma.

    Psychedelics and their potential

    USD 14.3 billion

    By 2028, the global market for drugs to treat depression is expected to develop this annual size.

    The third pillar of XPhyto is the market for psychoactive substances. While representatives of the German healthcare system are critical of substances such as THC, psilocybin or even mescaline, the trend in North America has long been moving in a different direction. There, star investors such as Bruce Linton and Peter Thiel are creating hype around psychedelic substances. Studies indicate that they can be used to treat various mental illnesses - provided the dose and quality are right.

    If it becomes established that psychoactive substances are effective against mental illnesses, suppliers of these products can hope for high demand. Market researchers such as Data Bridge are already forecasting that the market for the treatment of various forms of depression could grow to a volume of USD 14.3 billion worldwide by 2028. The market share in North America, Europe, Asia-Pacific and South America is expected to be roughly equal in each case. 5

    With business relationships in North America and Europe, XPhyto may be well- positioned to take advantage of this projected market development. Primarily, the company works with the active ingredients psilocybin and mescaline.

    XPhyto Biotech
    XPhyto CEO Hugh Rogers wants to create facts and convince customers with studies. Source: XPhyto Therapeutics Corp.

    Cards are reshuffled

    XPhyto's business is unique because of the makeup of its different business units. However, in 2022, management sees the greatest growth potential in diagnostics. A look at the competitive environment shows where XPhyto could be headed in the coming years, for example, the Korean company SD Biosensor, which claims to be the world's number 1 in the field of diagnostics. Here, however, the founder's story was somewhat different. SD Biosensor was only founded in 2010 and went public in the summer of 2021. Today, its market capitalization is just under EUR 4 billion. SD Biosensor is characterized by high margins - the EBITDA margin expected by the market for 2021 is 48.9%. 6

    Studies are imminent

    48.9%

    SD Biosensor's expected EBITDA margin in 2021

    XPhyto is also striving for efficiency in the field of diagnostics and emphasizes the platform idea: "We want to position XPhyto as a leading manufacturer of biosensors and combine the technology of our partner 3a with thin-film technology. That will create a platform from which we can build various solutions around rapid and cost-effective testing procedures" explains Hugh Rogers, CEO of XPhyto to researchanalyst.com. According to the company, numerous clinical test series for the PCR tests will be launched in the coming weeks and months, promising results within 1-2 weeks with a high probability of direct orders.

    airport corona testing
    A possible field of application for the 25min PCR test is the tourism industry, for example at airports. Source: Pixabay.com

    Rapid PCR tests are in vogue

    XPhyto is also conducting studies in the coming months in the area of innovative dosage forms and the use of psychedelics as medications, which can scientifically document the advantages of the respective technology. XPhyto expects these studies to provide catalysts for new business. In particular, the rapid PCR tests are expected to help the company achieve a breakthrough. As XPhyto points out, the market for such tests has recently gained considerable momentum: "The testing business is booming, and there is already a trend towards rapid PCR tests. Demand is very high", Rogers emphasizes.

    Early listing as an opportunity

    There are highly different approaches to the right financial setup in the biotech industry. While companies such as SD Biosensor are doing good business today with the big players in the industry, such as Roche, such partnerships are, of course, still pending at XPhyto. However, SD Biosensor, for example, was not listed on the stock market in its early phase between 2010 and 2021 and was able to quietly build a business. XPhyto, which was listed on the capital market early on, is looking for investors on the open market in the early stages of its business development. One could also say that the company is putting a lot on one card and exposing itself early to the agile capital market. Risk and opportunity with possible momentum included.

    However, the extent to which such an early investment opportunity can promise success for investors naturally depends heavily on the outcome of the outstanding clinical trials. It is not uncommon for biotechs to conduct research for years without any earnings to show for it. If success is foreseeable, institutional investors who accompanied the company at an early stage often cash out - for the majority of investors, the crumbs of the cake then remain.

    A good signal is when the biotech keeps receiving fresh funds. In view of the upcoming clinical test series in all areas, some of which are being carried out directly in cooperation with potential customers, XPhyto could now be on the verge of a significant upturn in business. Most recently, the company managed to complete a CAD 7 million capital raising. The primary objective of this measure was to fully acquire 3a-diagnostics GmbH and to initiate new business, the statement said.

    SWOT - a brief overview

    Strengths

    • Three promising business areas (diagnostics, dosage forms and psychedelics)
    • Rapid PCR test as growth driver
    • Already listed on the stock exchange in early company phase
    • Capital increase recently successfully completed
    • Platform approach

    Weaknesses

    • Decisive studies still pending

    Opportunities

    • Strong demand for Covid-19 test solutions
    • Potential around diagnosis of oral diseases and innovative dosage forms

    Risks

    • Competition from Asia
    • Market maturity of products not yet conclusively proven in some cases
    XPhyto Stock S&P500
    XPhyto was able to temporarily outperform the S&P 500 Pharma/Biotech in 2021. Most recently, there were signs of underperformance, which could be due to the capital increase and corresponding dilution. Source: S&P CapitalIQ Pro

    Conclusion and outlook

    XPhyto is a biotech company operating in three growth areas. The diagnostics business is very promising in light of the pandemic. XPhyto is also promisingly positioned in the diagnosis of other diseases, such as oral diseases, like periodontitis or scarlet fever and flu. The extent of the potential will be shown by clinical trials in the coming weeks and months, on which some customer orders may directly depend. The business with alternative dosage forms will also be demonstrated in the coming months in the form of clinical trials and has the potential to prevent application errors on the part of patients and save costs in the manufacture of medicines. With the business field around drugs and psychedelics, XPhyto walks on the paths of numerous star investors like Peter Thiel and Christian Angermayer. While this topic has not yet struck a chord with physicians and decision-makers in the healthcare sector in Germany, people in North America are more open-minded. As XPhyto is present in both regions, the company can push this speculative business field within a constructive environment.

    The coming weeks and months will be critical for XPhyto. If the company succeeds in acquiring customers and further developing the individual business areas, figures will soon be available that can be used as the basis for an even better assessment of the company's future growth. Until then, XPhyto remains a speculative stock with great blue sky potential.

    Reference:

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on researchanalyst.com. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Keyfacts
    ISIN: CA98421R1055
    Industry Biotechnology
    Last share price 0.817 EUR
    Number of shares (fully diluted) 93.82 Mio.
    Market capitalization 76.65 million EUR
    Share of insiders and institutional investors in the company 9,1%
    Gross Margin 67,9%
    Price-to-book ratio (P/B) 29.4
    Homepage www.xphyto.com
    CEO Hugh Rogers
    Source: S&P CapitalIQ Pro, as of 06.12.2021
    Media comments

    Author
    Autor
    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    More about the author

    Further analyses